Compare Ralph Lauren Corp (RL) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ralph Lauren Corp vs GeneDx Holdings Corp — how do they compare? Ralph Lauren Corp trades at $368.77 (market cap $21.52B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: Ralph Lauren Corp is far larger — about 10.5× GeneDx Holdings Corp's market cap, and Ralph Lauren Corp pays a 1.11% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ralph Lauren Corp for 84 Days and GeneDx Holdings Corp for 19 Days on average.
| RL | WGS | |
|---|---|---|
Market Cap | $21.52B | $2.04B |
Volume | 454,217 | 659,215 |
Sector | Consumer Cyclical | Health |
52-Week High | $414.25 | $167.51 |
52-Week Low | $309.29 | $34.51 |
Typical Hold Time | 84 Days | 19 Days |
Enterprise Value | $22.58B | $2.08B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ralph Lauren (RL) trades at $367.39, down 0.35% with a bearish technical signal despite strong fundamentals. The company demonstrates robust profitability with 70.27% gross margins and 37.54% ROE, while consistently beating earnings estimates. Recent news highlights global expansion through new store openings and AI-driven customer experience enhancements. Cash flow remains positive at $258.80M for 2025, supporting the $1.00 dividend declared for October 2026 payment.
The stock presents a compelling value opportunity with analyst consensus target of $456.67 representing 24% upside. Strong brand positioning and operational efficiency drive growth, though competitive pressures and market volatility pose risks. Institutional sentiment remains bullish with 67% buy ratings, suggesting confidence in the company's luxury market strategy and financial performance trajectory.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ralph Lauren Corp
Founded by designer Ralph Lauren in 1967, Ralph Lauren Corp. designs, markets, and distributes lifestyle products in North America, Europe, and Asia. Its products include apparel, footwear, eyewear, jewelry, leather goods, home products, and fragrances. The company's brands include Ralph Lauren Collection, Polo Ralph Lauren, Lauren Ralph Lauren, and Double RL. Distribution channels for Ralph Lauren include wholesale (including department stores and specialty stores), retail (including company-owned retail stores and e-commerce), and licensing.
Read more on RL →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
